Cell Therapy in Huntington's Disease

NeuroRx

Volumn 1, Issue 4, 2004, Pages 394-405

  Dunnett, Stephen B ^a   Rosser, Anne E ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

cell therapy; ex vivo gene therapy; fetal tissues; Huntington's disease; neural transplantation; neuroprotection; stem cells; trophic factors

Indexed keywords

NERVE GROWTH FACTOR;

ARTICLE; AUTOSOMAL DOMINANT DISORDER; CELL THERAPY; CHROMOSOME 4; COGNITIVE DEFECT; CORPUS STRIATUM; EX VIVO STUDY; EXCITOTOXICITY; GENE; GENE MUTATION; GENE THERAPY; HTT GENE; HUMAN; HUNTINGTON CHOREA; IN VIVO STUDY; MOLECULAR GENETICS; MOTOR DYSFUNCTION; NEOCORTEX; NEOSTRIATUM; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NERVE GRAFT; NEUROPATHOLOGY; NEUROPSYCHIATRY; NONHUMAN; STEM CELL TRANSPLANTATION; TRANSGENIC MOUSE; ANIMAL; CELL TRANSPLANTATION; DISEASE MODEL; FETAL TISSUE TRANSPLANTATION; NERVE CELL; REVIEW; TRANSPLANTATION;

ANIMALS; CELL TRANSPLANTATION; DISEASE MODELS, ANIMAL; FETAL TISSUE TRANSPLANTATION; HUMANS; HUNTINGTON DISEASE; NEOSTRIATUM; NEURONS; STEM CELL TRANSPLANTATION;

EID: 15444378095     PISSN: 15455343     EISSN: 15455351     Source Type: Journal    
DOI: 10.1602/neurorx.1.4.394     Document Type: Article

References (138)

1. Huntington's disease. In: Bates G., Harper P., and Jones A. (Eds) (2002), Oxford University Press, Oxford
2. Leegwater-Kim J., and Cha J. The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration. NeuroRx 1 (2004) 128-138
3. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
4. DiFiglia M., Sapp E., Chase K., Davies S., Bates G., Vonsattel J.-P., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277 (1997) 1990-1993
5. Davies S., Turmaine M., Cozens B., DiFiglia M., Sharp A., Ross C., et al. Formation of neuronal intranuclear inclusions (NII) underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90 (1997) 537-548
6. Leroi I., and Michalon M. Treatment of the psychiatric manifestations of Huntington's disease: a review of the literature. Can J Psychiatry 43 (1998) 933-940
7. Nance M., and Westphal B. Comprehensive care in Huntington's disease. In: Bates G., Harper P., and Jones A. (Eds). Huntington's disease (2002), Oxford University Press, Oxford 475-500
8. Coyle J., and Schwarcz R. Lesions of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 263 (1976) 244-246
9. Mason S., Sanberg P., and Fibiger H. Kainic acid lesions of the striatum dissociate amphetamine and apomorphine stereotypy: similarities to Huntington's chorea. Science 201 (1978) 352-355
10. Sanberg P., and Coyle J. Scientific approaches to Huntington's disease. CRC Crit Rev Clin Neurobiol 1 (1984) 1-44
11. Schwarcz R., Hökfelt T., Fuxe K., Jonsson G., Goldstein M., and Terenius L. Ibotenic acid-induced neuronal degeneration: a morphological and neurochemical study. Exp Brain Res 37 (1979) 199-216
12. Schwarcz R., Whetsell W., and Mangano R. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219 (1983) 316-318
13. Brasted P., Döbrössy M., Eagle D., Nathwani F., Robbins T., and Dunnett S. Operant analysis of striatal dysfunction. In: Emerich D., Dean R., and Sanberg P. (Eds). Innovative models of CNS diseases: from molecules to therapy (2000), Humana, Totowa, NJ 249-273
14. Borlongan C., Koutouzis T., and Sanberg P. 3-Nitropropionic acid animal model and Huntington's disease. Neurosci Biobehav Rev 21 (1997) 289-293
15. Beal M., Brouillet E., Jenkins B., Henshaw R., Rosen B., and Hyman B. Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J Neurochem 61 (1993) 1147-1150
16. Gu M., Gash M., Mann V., Javoy-Agid F., Cooper J., and Schapira A. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 39 (1996) 385-389
17. Palfi S., Ferrante R., Brouillet E., Beal M., Dolan R., Guyot M., et al. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J Neurosci 16 (1996) 3019-3025
18. Page K., Meldrum A., and Dunnett S. The 3-nitroproprionic acid (3NPA) model of Huntington's disease: do alterations in the expression of metabolic mRNAs predict the development of striatal pathology. In: Sanberg P., Nishino H., and Borlongan C. (Eds). Mitochondrial inhibitors as tools for neurobiology (1999), Humana, Totowa, NJ 141-156
19. Menalled L., and Chesselet M. Mouse models of Huntington's disease. Trends Pharmacol Sci 23 (2002) 32-39
20. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996) 493-506
21. Carter R., Lione L., Humby T., Mangiarini L., Mahal A., Bates G., et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 19 (1999) 3248-3257
22. Lione L., Carter R., Bates G., Morton A., and Dunnett S. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J Neurosci 19 (1999) 10428-10437
23. Tabrizi S., Workman J., Hart P., Mangiarini L., Mahal A., Bates G., et al. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol 47 (2000) 80-86
24. Cha J., Kosinski C., Kerner J., Alsdorf S., Mangiarini L., Davies S., et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc Natl Acad Sci USA 95 (1998) 6480-6485
25. Murphy K., Carter R., Lione L., Mangiarini L., Mahal A., Bates G., et al. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J Neurosci 20 (2000) 5115-5123
26. Yamamoto A., Lucas J., and Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101 (2000) 57-66
27. Dunnett S., Nathwani F., and Björklund A. The integration and function of striatal grafts. Prog Brain Res 127 (2000) 345-380
28. Mayer E., Brown V., Dunnett S., and Robbins T. Striatal graft-associated recovery of a lesion-induced performance deficit in the rat requires learning to use the transplant. Eur J Neurosci 4 (1992) 119-126
29. Döbrössy M., and Dunnett S. Striatal grafts alleviate deficits in response execution in a lateralised reaction time task. Brain Res Bull 47 (1998) 585-593
30. Dunnett S. Functional repair of striatal systems by neural transplants: evidence for circuit reconstruction. Behav Brain Res 66 (1995) 133-142
31. Wictorin K. Anatomy and connectivity of intrastriatal striatal transplants. Prog Neurobiol 38 (1992) 611-639
32. Xu Z., Wilson C., and Emson P. Synaptic potentials evoked in spiny neurons in rat neostriatal grafts by cortical and thalamic stimulation. J Neurophysiol 65 (1991) 477-493
33. Nakao N., Ogura M., Nakai K., and Itakura T. Embryonic striatal grafts restore neuronal activity of the globus pallidus in a rodent model of Huntington's disease. Neuroscience 88 (1999) 469-477
34. Campbell K., Kalén P., Wictorin K., Lundberg C., Mandel R., and Björklund A. Characterization of GABA release from intrastriatal striatal transplants: dependence on host-derived afferents. Neuroscience 53 (1993) 403-415
35. Sirinathsinghji D., Dunnett S., Isacson O., Clarke D., Kendrick K., and Björklund A. Striatal grafts in rats with unilateral neostriatal lesions. II. In vivo monitoring of GABA release in globus pallidus and substantia nigra. Neuroscience 24 (1988) 803-811
36. Sirinathsinghji D., Heavens R., Torres E., and Dunnett S. Cholecystokinin-dependent regulation of host dopamine inputs to striatal grafts. Neuroscience 53 (1993) 651-663
37. Dunnett S., Carter R., Watts C., Torres E., Mahal A., Mangiarini L., et al. Striatal transplantation in a transgenic mouse model of Huntington's disease. Exp Neurol 154 (1998) 31-40
38. van Dellen A., Deacon R., York D., Blakemore C., and Hannan A. Anterior cingulate cortical transplantation in transgenic Huntington's disease mice. Brain Res Bull 56 (2001) 313-318
39. Morton A., Lagan M., Skepper J., and Dunnett S. Progressive formation of inclusions in the brains of mice transgenic for the human Huntington's disease mutation parallels neurological decline. J Neurocytol 29 (2000) 679-702
40. Vonsattel J.-P., Myers R., and Stevens T. Neuropathologic classification of Huntington's disease. J Neuropathol Exp Neurol 44 (1985) 559-577
41. MacDonald V., and Halliday G. Pyramidal cell loss in motor cortices in Huntington's disease. Neurobiol Dis 10 (2002) 378-386
42. Mazurek M., Garside S., and Beal M. Cortical peptide changes in Huntington's disease may be independent of striatal degeneration. Ann Neurol 41 (1997) 540-547
43. Greenamyre J., and Shoulson I. We need something better, and we need it now: fetal striatal transplantation in Huntington's disease?. Neurology 58 (2002) 675-676
44. Olanow C., Kordower J., and Freeman T. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 19 (1996) 102-109
45. Dunnett S., Björklund A., and Lindvall O. Cell therapy in Parkinson's disease -stop or go?. Nat Rev Neurosci 2 (2001) 365-369
46. Peschanski M., saro P., and Hantraye P. Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease. Neuroscience 68 (1995) 273-285
47. Freeman T., Sanberg P., and Isacson O. Development of the human striatum: implications for fetal striatal transplantation in the treatment of Huntington's disease. Cell Transplant 4 (1995) 539-545
48. Rosser A., Barker R., Armstrong R., Elneil S., Jain M., Hurelbrink C., et al. Staging and preparation of human fetal striatal tissue for UK study of neural transplantation in Huntington's disease. Cell Transplant 12 (2003) 679-686
49. Pundt L., Kondoh T., Conrad J., and Low W. Transplantation of human striatal tissue into a rodent model of Huntington's disease: phenotypic expression of transplanted neurons and host-to-graft innervation. Brain Res Bull 39 (1996) 23-32
50. Grasbon-Frodl E., Nakao N., Lindvall O., and Brundin P. Developmental features of human striatal tissue transplanted in a rat model of Huntington's disease. Neurobiol Dis 3 (1997) 299-311
51. Hurelbrink C., Armstrong R., Barker R., Dunnett S., and Rosser A. Hibernated human fetal striatal tissue: successful transplantation in a rat model of Huntington's disease. Cell Transplant 9 (2000) 743-749
52. Graybiel A., Liu F., and Dunnett S. Intrastriatal grafts derived from fetal striatal primordia. 1. Phenotypy and modular organization. J Neurosci 9 (1989) 3250-3271
53. Smart I., and Sturrock R. Ontogeny of the neostriatum. In: Divac I., and Öberg R. (Eds). The neostriatum (1979), Pergamon, New York 127-146
54. Pakzaban P., Deacon T., Burns L., and Isacson O. Increased proportion of acetylcholinesterase-rich zones and improved morphological integration in host striatum of fetal grafts derived from the lateral but not the medial ganglionic eminence. Exp Brain Res 97 (1993) 13-22
55. Deacon T., Pakzaban P., and Isacson O. The lateral ganglionic eminence is the origin of cells committed to striatal phenotypes: neural transplantation and developmental evidence. Brain Res 668 (1994) 211-219
56. Nakao N., Odin P., and Brundin P. Selective sub-dissection of the striatal primordium for cultures affects the yield of DARPP-32-containing neurones. NeuroReport 5 (1994) 1081-1084
57. Olsson M., Campbell K., Wictorin K., and Björklund A. Projection neurons in fetal striatal transplants are predominantly derived from the lateral ganglionic eminence. Neuroscience 69 (1995) 1169-1182
58. Naimi S., Jeny R., Hantraye P., Peschanski M., and Riche D. Ontogeny of human striatal DARPP-32 neurons in fetuses and following xenografting to the adult rat brain. Exp Neurol 137 (1996) 15-25
59. Marín O., Anderson S., and Rubenstein J. Origin and molecular specification of striatal interneurons. J Neurosci 20 (2000) 6063-6076
60. Watts C., Dunnett S., and Rosser A. Effect of embryonic donor age and dissection on the DARPP-32 content of cell suspensions used for intrastriatal transplantation. Exp Neurol 148 (1997) 271-280
61. Grasbon-Frodl E., Nakao N., Lindvall O., and Brundin P. Phenotypic development of the human embryonic striatal primordium: a study of cultured and grafted neurons from the lateral and medial ganglionic eminence. Neuroscience 73 (1996) 171-183
62. Kremer B. Clinical neurology of Huntington's disease. In: Bates G., Harper P., and Jones A. (Eds). Huntington's disease (2002), Oxford University Press, Oxford 28-61
63. Craufurd D., and Snowden J. Neuropsychological and neuropsychiatric aspects of Huntington's disease. In: Bates G., Harper P., and Jones A. (Eds). Huntington's disease (2002), Oxford University Press, Oxford 62-94
64. Kieburtz K., Penney J., Como P., Ranen N., Shoulson I., Feigin A., et al. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord 11 (1996) 136-142
65. Bachoud-Lévi A., Maison P., Bartolomeo P., Boiss M., Dalla Barba G., Ergis A., et al. Retest effects and cognitive decline in longitudinal follow-up of patients with early HD. Neurology 56 (2001) 1052-1058
66. Ho A., Brown R., Hodges J., Ane M., Snowden J., Thompson J., et al. Profile of cognitive progression in Huntington's disease. Neurology 61 (2003) 1702-1706
67. Quinn N., Brown R., Craufurd D., Goldman S., Hodges J., Kieburtz K., et al. Core assessment programme for intracerebral transplantation in Huntington's disease (CAPIT-HD). Mov Disord 11 (1996) 143-150
68. Norman A., Thomas S., Pratt R., Samaratunga R., and Sanberg P. T1 and T2 weighted magnetic resonance imaging of excitotoxin lesions and neural transplants in rat brain in vivo. Exp Neurol 109 (1990) 164-170
69. Denys A., Leroy-Willig A., Riche D., and Hantraye P. MR appearance of neural grafts in a primate model of Huntington disease. Am J Roentgenol 158 (1992) 215-216
70. Torres E., Fricker R., Hume S., Myers R., Opacka-Juffry J., Ashworth S., et al. Assessment of striatal graft viability in the rat in vivo using a small diameter PET scanner. NeuroReport 6 (1995) 2017-2021
71. Boer G. Ethical guidelines for the use of human embryonic or fetal tissue for experimental and clinical neurotransplantation and research. J Neurol 242 (1994) 1-13
72. Sauer H., and Brundin P. Effects of cool storage on survival and function of intrastriatal ventral mesencephalic grafts. Rest Neurol Neurosci 2 (1991) 123-135
73. Hurelbrink C., Tyers P., Armstrong R., Dunnett S., Barker R., and Rosser A. Long-term hibernation of human fetal striatal tissue does not adversely affect its differentiation in vitro or graft survival: implications for clinical trials in Huntington's disease. Cell Transplant 12 (2003) 687-695
74. Kopyov O., Jacques S., Lieberman A., Duma C., and Eagle K. Safety of intrastriatal neurotransplantation for Huntington's disease patients. Exp Neurol 119 (1998) 97-108
75. Kopyov O., Jacques S., Kurth M., Philpott L., Lee A., Patterson M., et al. Fetal transplantation for Huntington's disease: clinical studies. In: Freeman T., and Kordower J. (Eds). Cell transplantation for neurological disorders (1998), Humana Press, Totowa, NJ 95-134
76. Philpott L., Kopyov O., Lee A., Jacques S., Duma C., Caine S., et al. Neuropsychological functioning following fetal striatal transplantation in Huntington's chorea: three case presentations. Cell Transplant 6 (1997) 203-212
77. Hoang T., Bluml S., Dubowitz D., Moats R., Kopyov O., Jacques D., et al. Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology 50 (1998) 1033-1040
78. Ross B., Hoang T., Blüml S., Dubowitz D., Kopyov O., Jacques D., et al. In vivo magnetic resonance spectroscopy of human fetal neural transplants. NMR Biomed 12 (1999) 221-236
79. Palfi S., Nguyen J., Brugières P., LeGuerinel C., Hantraye P., Rémy P., et al. MRI-stereotactical approach for neural grafting in basal ganglia disorders. Exp Neurol 150 (1998) 272-281
80. Bachoud-Lévi A., Bourdet C., Brugières P., Nguyen J., Grandmougin T., Haddad B., et al. Safety and tolerability assessment of intrastriatal neural allografts in Huntington's disease patients. Exp Neurol 161 (2000) 194-202
81. Bachoud-Lévi A., R,my P., Nguyen J., Brugières P., Lefaucheur J., Bourdet C., et al. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 356 (2000) 1975-1979
82. Gaura V., Bachoud-Lévi A., Ribeiro M., Nguyen J., Frouin V., Baudic S., et al. Striatal neural grafting improves cortical metabolism in Huntington's disease patients. Brain 127 (2004) 65-72
83. Hauser R., Furtado S., Cimino C., Delgado H., Eichler S., Schwartz S., et al. Bilateral human fetal striatal transplantation in Huntington's disease. Neurology 58 (2002) 687-695
84. Freeman T., Cicchetti F., Hauser R., Deacon T., Li X., Hersch S., et al. Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. Proc Natl Acad Sci USA 97 (2000) 13877-13882
85. Rosser A., Barker R., Guillard J., Harrower T., Watts C., Pickard J., et al. Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report (ISRCTN no 36485475). J Neurol Neurosurg Psychiatry 73 (2002) 678-685
86. Fink J., Schumacher J., Ellias S., Palmer E., Saint-Hilaire M., Shannon K., et al. Porcine xenografts in Parkinson's disease and Huntington's disease patients: preliminary results. Cell Transplant 9 (2000) 273-278
87. Pakzaban P., Deacon T., Burns L., Dinsmore J., and Isacson O. A novel mode of immunoprotection of neural xenotransplants: masking of donor major histocompatibility complex class I enhances transplant survival in the central nervous system. Neuroscience 65 (1995) 983-996
88. Deacon T., Schumacher J., Dinsmore J., Thomas C., Palmer P., Kott S., et al. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. Nat Med 3 (1997) 350-353
89. Nauert G., and Freeman T. Low-pressure aspiration abortion for obtaining embryonic and early gestational fetal tissue for research purposes. Cell Transplant 3 (1994) 147-151
90. Seaberg R., and van der Kooy D. Stem and progenitor cells: the premature desertion of rigorous definitions. Trends Neurosci 26 (2003) 125-131
91. Armstrong R., and Svendsen C. Neural stem cells: from cell biology to cell replacement. Cell Transplant 9 (2000) 139-152
92. Reynolds B., Tetzlaff W., and Weiss S. A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. J Neurosci 12 (1992) 4565-4574
93. Tropepe V., Sibilia M., Ciruna B., Rossant J., Wagner E., and van der Kooy D. Distinct neural stem cells proliferate in response to EGF and FGF in the developing mouse telencephalon. Dev Biol 208 (1999) 166-188
94. Svendsen C., ter Borg M., Armstrong R., Rosser A., Chandran S., Ostenfeld T., et al. A new method for the rapid and long term growth of human neural precursor cells. J Neurosci Meth 85 (1998) 141-152
95. Carpenter M. In vitro expansion of a multipotent population of human neural progenitor cells. Exp Neurol 158 (1999) 265-278
96. Jain M., Armstrong R., Tyers P., Barker R., and Rosser A. GABAergic immunoreactivity is predominant in neurons derived from expanded human neural precursor cells in vitro. Exp Neurol 182 (2003) 113-123
97. Qian X., Shen Q., Goderie S., He W., Capela A., Davis A., et al. Timing of CNS cell generation: a programmed sequence of neuron and glial cell production from isolated murine cortical stem cells. Neuron 28 (2000) 69-80
98. Sanai N., Tramontin A., Quinones-Hinojosa A., Barbaro N., Gupta N., Kunwar S., et al. Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature 427 (2004) 740-744
99. Rosser A., Tyers P., and Dunnett S. The morphological development of neurons derived from EGF- and FGF-2-driven human CNS precursors depends on their site of integration in the neonatal rat brain. Eur J Neurosci 12 (2000) 2405-2413
100. Fricker R., Carpenter M., Winkler C., Greco C., Gates M., and Björklund A. Site-specific migration and neuronal differentiation of human neural progenitor cells after transplantation in the adult rat brain. J Neurosci 19 (1999) 5990-6005
101. Englund U., Björklund A., Wictorin K., Lindvall O., and Kokaia M. Grafted neural stem cells develop into functional pyramidal neurons and integrate into host cortical circuitry. Proc Natl Acad Sci USA 99 (2002) 17089-17094
102. Armstrong R., Watts C., Svendsen C., Dunnett S., and Rosser A. Survival, neuronal integration and fibre outgrowth of propagated human neural precursor grafts in an animal model of Huntington's disease. Cell Transplant 9 (2000) 55-64
103. Skogh C., Parmar M., and Campbell K. The differentiation potential of precursor cells from the mouse lateral ganglionic eminence is restricted by in vitro expansion. Neuroscience 120 (2003) 379-385
104. Thompson J., Istkovitz-Eldor J., Shapiro S., Waknitz M., Swiergiel J., Marshall V., et al. Embryonic stem cell lines derived from human blastocysts. Science 282 (1998) 1145-1147
105. Reubinoff B., Pera M., Fong C., Trounson A., and Bongso A. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol 18 (2000) 399-404
106. Zhang S., Wernig M., Duncan I., Brüstle O., and Thomson J. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol 19 (2001) 1129-1133
107. Kim J., Auerbach J., Rodriguez-Gomez J., Velasco I., Gavin D., Lumelsky N., et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 418 (2002) 50-56
108. Wichterle H., Lieberam I., Porter J., and Jessell T. Directed differentiation of embryonic stem cells into motor neurons. Cell 110 (2002) 385-397
109. Shamblott M., Axelman J., Wang S., Bugg E., Littlefield J., Donovan P., et al. Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc Natl Acad Sci USA 95 (1998) 13726-13731
110. Turnpenny L., Brickwood S., Spalluto C., Piper K., Cameron I., Wilson D., et al. Derivation of human embryonic germ cells: an alternative source of pluripotent stem cells. Stem Cells (Dayt) 21 (2003) 598-609
111. Long Y., and Yang K. Bone marrow derived cells for brain repair: recent findings and current controversies. Curr Mol Med 3 (2003) 719-725
112. Jain M., Armstrong R., Barker R., and Rosser A. Cellular and molecular aspects of striatal development. Brain Res Bull 55 (2001) 533-540
113. Fawcett J., Rosser A., and Dunnett S. Brain damage, brain repair (2001), Oxford University Press, Oxford
114. Ventimiglia R., Mather P., Jones B., and Lindsay R. The neurotrophins BDNF, NT-3 and NT-4/5 promote survival and morphological and biochemical differentiation of striatal neurons in vitro. Eur J Neurosci 7 (1995) 213-222
115. Nakao N., Odin P., Lindvall O., and Brundin P. Differential trophic effects of basic fibroblast growth factor, insulin-like growth factor-1, and neurotrophin-3 on striatal neurons in culture. Exp Neurol 138 (1996) 144-157
116. Petersén A., and Brundin P. Effects of ciliary neurotrophic factor on excitotoxicity and calcium-ionophore A23187-induced cell death in cultured embryonic striatal neurons. Exp Neurol 160 (1999) 402-412
117. Alberch J., Pérez-Navarro E., and Canals J. Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease. Brain Res Bull 57 (2002) 817-822
118. Perez-Navarro E., Canudas A., Åkerud P., Alberch J., and Arenas E. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease. J Neurochem 75 (2000) 2190-2199
119. Alexi T., Hughes P., Faull R., and Williams C. 3-Nitropropionic acid's lethal triplet: cooperative pathways of neurodegeneration. NeuroReport 9 (1998) R57-R64
120. Anderson K., Panayotatos N., Corcoran T., Lindsay R., and Wiegand S. Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease. Proc Natl Acad Sci USA 93 (1996) 7346-7351
121. Mittoux V., Ouary S., Monville C., Lisovoski F., Poyot T., Cond F., et al. Corticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration. J Neurosci 22 (2002) 4478-4486
122. McBride J., During M., Wuu J., Chen E., Leurgans S., and Kordower J. Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp Neurol 181 (2003) 213-223
123. Raymon H., Thode S., and Gage F. Application of ex vivo gene therapy in the treatment of Parkinson's disease. Exp Neurol 144 (1997) 82-91
124. Tuszynski M. Growth-factor gene therapy for neurodegenerative disorders. Lancet Neurol 1 (2002) 51-57
125. Schumacher J., Short M., Hyman B., Breakefield X., and Isacson O. Intracerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids. Neuroscience 45 (1991) 561-570
126. Frim D., Uhler T., Short M., Ezzedine Z., Klagsbrun M., Breakefield X., et al. Effects of biologically delivered NGF, BDNF and bFGF on striatal excitotoxic lesions. NeuroReport 4 (1993) 367-370
127. Dunnett S., and Mayer E. Neural grafts, growth factors and trophic mechanisms of recovery. In: Hunter A., and Clarke M. (Eds). Neurodegeneration (1992), Academic Press, New York 183-217
128. Tan S., and Aebischer P. The problems of delivering neuroactive molecules to the CNS. Ciba Found Symp 196 (1996) 211-236
129. Emerich D., Lindner M., Winn S., Chen E., Frydel B., and Kordower J. Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. J Neurosci 16 (1996) 5168-5181
130. Emerich D., Bruhn S., Chu Y., and Kordower J. Cellular delivery of CNTF but not NT-4/5 prevents degeneration of striatal neurons in a rodent model of Huntington's disease. Cell Transplant 7 (1998) 213-225
131. Emerich D., Cain C., Greco C., Saydoff J., Hu Z., Liu H., et al. Cellular delivery of human CNTF prevents motor and cognitive dysfunction in a rodent model of Huntington's disease. Cell Transplant 6 (1997) 249-266
132. Emerich D., Winn S., Hantraye P., Peschanski M., Chen E., Chu Y., et al. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature 386 (1997) 395-399
133. Mittoux V., Joseph J., Cond F., Palfi S., Dautry C., Poyot T., et al. Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease. Hum Gene Ther 11 (2000) 1177-1187
134. Buchser E., Goddard M., Heyd B., Joseph J., Favre J., Detribolet N., et al. Immunoisolated xenogeneic chromaffin cell therapy for chronic pain. Initial clinical-experience. Anesthesiology 85 (1996) 1005-1012
135. Aebischer P., Schluep M., Déglon N., Joseph J., Hirt L., Heyd B., et al. Intrathecal delivery of CNTF using encapsulated genetically-modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 2 (1996) 696-699
136. Bachoud-Lévi A., D,glon N., Nguyen J., Bloch J., Bourdet C., Winkel L., et al. Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum Gene Ther 11 (2000) 1723-1729
137. Sramka M., Rattaj M., Molina H., Vojtassak J., Belan V., and Ruzicky E. Stereotactic technique and pathophysiological mechanisms of neurotransplantation in Huntington's chorea. Stereotact Funct Neurosurg 58 (1992) 79-83
138. Madrazo I., Franco-Bourland R., Castrejon H., Cuevas C., and Ostrosky-Solis F. Fetal striatal homotransplantation for Huntington's disease: first two case reports. Neurol Res 17 (1995) 312-315